Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Theravance Biopharma Inc
TBPH | US
14.00
USD0.43
3.17%
TBPH | US
Loading StockChartView...
About Theravance Biopharma Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
14.00
Open
13.34
High
14.12
Low
13.29
Theravance Biopharma Inc. a biopharmaceutical company discovers develops and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI a once-daily nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program as well as Viatris Inc. Theravance Biopharma Inc. was incorporated in 2013 and is based in George Town the Cayman Islands.
View LessTBPH | US
Risk
99.0
Sharpe
0.72
Luna's Score
54/100
Recommendation
Hold
Luna says (TBPH | US)
What's Working
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
130.0%1 month
99.0%3 months
63.4%6 months
60.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
9.91
Price to book
2.18
Debt to equity
0.24
Debt to assets
0.13
Ent. to EBITDA
-9.69
Ent. to rev.
6.00
PEG
-0.05
Other Fundamentals
EBITDA
-39.17M
MarketCap
684.91M
MarketCap(USD)
684.91M
Div. yield
-
Op. margin
-89.46
Erngs. growth
-
Rev. growth
3.70
Ret. on equity
-19.27
Short ratio
24.09
Short perc.
20.90
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
6.76
Range1M
7.52
Range3M
7.95
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.34
Price X volume
16.87M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.69 | 0.53 | Cheaper |
| Ent. to Revenue | 6.00 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.18 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 63.43 | 72.80 | Par |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 684.91M | 3.66B | Emerging |
